Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Daniela Di Mauro, Andrea D'Alessio, Davide Resta, Carmelo Fortugno, Simonetta Villa, Luca Geroli, S. Cecchini, Antonello Quadri
Publikováno v:
Tumori Journal. 102:S65-S68
Purpose Cetuximab and panitumumab are monoclonal antibody inhibitors that bind the epidermal growth factor receptor (EGFR) currently used in the treatment of metastatic colorectal cancer. The main adverse event related to EGFR inhibitors (EGFR-Is) is
New Drugs in the Treatment of Elderly Patients with Metastatic Castration-Resistance Prostate Cancer
Publikováno v:
Tumori Journal. 102:361-366
Treatment of prostate cancer is continually evolving and new therapies have become available. However, the management of elderly patients is challenging due to their age and comorbidities. Androgen deprivation therapy remains the mainstay treatment o
Autor:
Carlo Resteghini, Paolo Bossi, Carla Ripamonti, Patrizia Giannatempo, Nicoletta Zilembo, Andrea Necchi, Laura Ferrari, M.A. Pessi
Publikováno v:
Tumori Journal. 101:692-696
Aims and Background There is a paucity of data regarding the incidence, intensity, and treatment of nausea and vomiting during the intercycle periods of chemotherapy (CHT). The aims of the study were to assess the incidence and intensity of intercycl
Autor:
Saverio Cinieri, M.C. Chetri, Angelo Nacci, Nicola Calvani, Palma Fedele, E. Mazzoni, Laura Orlando, Chiara Caliolo, A. Marino, Annamaria Quaranta, Pasqualinda Ferrara, Margherita Cinefra, Paola Schiavone, Francesco Sponziello, Stefania Eufemia Lutrino, P. Rizzo, M. D'Amico
Publikováno v:
Tumori Journal. 101:524-528
Aims and background Few data describe the activity of panitumumab after cetuximab-irinotecan-based regimen failure in patients with KRAS wild-type metastatic colorectal cancer (WT MCRC). Methods The aim of this study is to assess if panitumumab has s
Autor:
Kucharz, Jakub, Dumnicka, Paulina, Kuźniewski, Marek, Kuśnierz-Cabala, Beata, Herman, Roman, Krzemieniecki, Krzysztof
Publikováno v:
Tumori Journal. 101:555-559
Aims and background Clinical practice shows significant differences in treatment outcomes and toxicity of sunitinib across patients. This retrospective study assessed early predictive markers for progression-free survival (PFS) in patients with metas
Autor:
Jacopo Giuliani, Andrea Bonetti
Publikováno v:
Tumori Journal. 101:347-352
Introduction The treatment of patients with metastatic breast cancer (mBC) is one of the most difficult problems in clinical oncology. Clinical trial results suggest that novel therapies may be having a favorable impact on the survival of mBC patient
Autor:
Lorenza Rimassa, Armando Santoro, Antonio Gasbarrini, Bruno Daniele, Camillo Porta, Domenico Germano, Maria Lamar, Stefania Salvagni, Terri Goldberg, Gianluca Masi, Giovanni Abbadessa
Publikováno v:
Tumori Journal. 101:139-143
In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most co
Publikováno v:
Tumori Journal. 101:30-35
Background Elderly patients with metastatic breast cancer (MBC) have more problems receiving chemotherapy than younger patients, especially with the presence of multiple comorbidities, adverse drug events and functional decline. Low-dose oral adminis
Publikováno v:
Tumori Journal. 99:e241-e244
Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as neoadjuvant therapy is interesting because of the low toxicity profile o
Publikováno v:
Tumori Journal. 100:e290-e292
Randomized clinical trials are the gold standard to test the efficacy of an intervention within a specified patient population. However, the results of the trials may not be generalizable to routine clinical practice. Observational cohort studies may